EG 427
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $43.2Mattributed |
|---|---|
| Latest round | series-b, $29.2M, 2025-02-15attributed |
| Founded | 2021 |
| Headquarters | Paris, France |
| Industry | bio |
| Stage | series-b+ |
| Website | eg427.com |
EG 427 is a Paris-based biotech developing DNA medicines on a non-replicative Herpes Simplex Virus 1 platform that delivers durable gene expression to peripheral neurons. It focuses on patients with severe localized chronic diseases of the peripheral nervous system, starting with bladder disorders. HSV-1 latency lets it deliver large payloads.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-02-15 | series-b | $29.2M | undisclosed |
Detected tech stack
Cloudflare, PHP, YouTube, Unpkg, jsDelivr, Plesk, core-js, Alpine.js
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $29.2M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $43.2M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | eg427.com, read 2026-05-02 |
| Description | self-reported | eg427.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.